🌿 Medical Cannabis Dosing Titration Simulator

Start Low — The First Dose in a Cannabis-Naive Patient

Individual response to THC varies widely, so treatment begins at the smallest plausible dose.

• 1–2.5 mg: Typical starting dose (THC, cannabis-naive)
• CB1: Endocannabinoid receptor (primary psychoactive target)
• High: Inter-patient variability (metabolism, tolerance differ)
• Elevated: Naive ED-visit risk (without slow titration)

Why start this low

Placeholder: narrow therapeutic index makes small starting doses safer.

Patient factors considered

Placeholder: age, weight, prior use, and comorbidities shape the starting dose.

Setting expectations

Placeholder: patients are told effects build slowly across visits, not one dose.

Assessing Effect — Route-Specific Onset Timing

Adequate observation time must pass before judging whether a dose worked.

• 2–10 min: Inhaled onset (peak ~30 min)
• 30–120 min: Edible onset (peak 2–4 hours)
• 6–8 hr: Edible duration (longer than inhaled)
• Re-dosing early: Common error (before onset completes)

Inhaled route timing

Placeholder: fast onset allows quick, incremental effect checks.

Edible route timing

Placeholder: delayed onset risks impatient, stacked re-dosing.

Why waiting matters

Placeholder: judging too early causes accidental overdose later.

Gradual Dose Increase When Relief Is Inadequate

Small stepwise increases are made only when relief is insufficient and no side effects appeared.

• 1–2.5 mg: Typical step size (per increase)
• Days: Minimum interval (between increases)
• No relief AND no effects: Rule (both required to raise dose)
• Slow convergence: Goal (toward effective dose)

Step-wise increase logic

Placeholder: raise dose only in small, spaced increments.

Monitoring between steps

Placeholder: patient logs relief and any psychoactive symptoms.

When to pause increases

Placeholder: any unwanted effect halts further dose increases.

Careful Titration Toward the Therapeutic Window

Titration continues while watching the gap between relief and unwanted psychoactive effects.

• Narrow: Therapeutic window (relief vs. side effects)
• Anxiety: Key side effect (most reported at high dose)
• Weekly: Monitoring cadence (typical follow-up)
• Bidirectional: Adjustment direction (up or down as needed)

Balancing two curves

Placeholder: relief and side-effect curves are tracked together.

Signs of overshoot

Placeholder: anxiety, sedation, or impairment signal reducing dose.

Route switching

Placeholder: some patients change route to ease titration control.

Individualized Optimal Dose Within the Therapeutic Window

Titration ends once a stable dose delivers relief without excessive psychoactive effect.

• Optimal dose found: Outcome (individualized, stable)
• Edible overdose: Common ED cause (delayed-onset re-dosing)
• No relief: Under-dosing risk (patient discontinues therapy)
• Excess psychoactivity: Over-dosing risk (anxiety, impairment, ED visits)

What success looks like

Placeholder: consistent relief at the lowest effective, tolerated dose.

Avoiding both failure modes

Placeholder: neither under-dosed nor over-dosed extremes serve the patient.

Maintaining the window

Placeholder: periodic reassessment keeps dosing within the sweet spot.

Placeholder highlight: edible overdoses are a leading avoidable ED visit cause.